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Effectiveness of monovalent rotavirus vaccine in
Bolivia: case-control study
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Abstract
Objective To evaluate the effectiveness of two doses of a monovalent
rotavirus vaccine (RV1) against hospital admission for rotavirus in Bolivia.
Design Case-control study.
Setting Six hospitals in Bolivia, between March 2010 and June 2011.
Participants 400 hospital admissions for rotavirus, 1200 non-diarrhea
hospital controls, and 718 rotavirus negative hospital controls.
Main outcome measures Odds of antecedent vaccination between
case patients and controls; effectiveness of vaccination ((1–adjusted
odds ratio)×100), adjusted for age and other confounders; and stratified
effectiveness by dose, disease severity, age group, and serotype.
Results In comparison with non-diarrhea controls, case patients were
more likely to be male and attend day care but less likely to have chronic
underlying illness, higher level maternal education, and telephones and
computers in their home. Rotavirus negative controls were somewhat
more similar to case patients but also were more likely to be male and
attend day care and less likely to have higher level maternal education
and computers in their homes. The adjusted effectiveness of RV1 against
hospital admission for rotavirus was 69% (95% confidence interval 54%
to 79%) with rotavirus negative controls and 77% (65% to 84%) with
non-diarrhea controls. The effectiveness of one dose of RV1 was 36%
and 56%, respectively. With both control groups, protection was
sustained through two years of life, with similar efficacy against hospital
admission among children under 1 year (64% and 77%) and over 1 year
of age (72% and 76%). RV1 provided significant protection against
diverse serotypes, partially and fully heterotypic to the G1P[8] vaccine.
Effectiveness using the two control groups was 80% and 85% against
G9P[8], 74% and 93%% against G3P[8], 59% and 69% against G2P[4],
and 80% and 87% against G9P[6] strains.
Conclusion Themonovalent rotavirus vaccine conferred high protection
against hospital admission for diarrhea due to rotavirus in Bolivian
children. Protection was sustained through two years of life against
diverse serotypes different from the vaccine strain.
Introduction
TheWorld Health Organization recommends two live attenuated
oral rotavirus vaccines, a monovalent RIX4144 strain human
vaccine (RV1, Rotarix, GlaxoSmithKline Biologicals) and a
pentavalent bovine-human WC3 reassortant vaccine (RV5,
RotaTeq, Merck Vaccines, Whitehouse Station, NJ), for all
children worldwide to help to control the large burden of deaths
and hospital admissions due to rotavirus.1 An outstanding
question for the global community is whether oral rotavirus
vaccines will work well under routine conditions of public health
programs, particularly in countries with high mortality where
they potentially offer the greatest life saving benefits. Rotavirus
vaccines have performed well in middle and high income
settings, where efficacy has ranged from 77% to 98%.2-5 In
contrast, the efficacy of these vaccines in controlled clinical
trial conditions was lower in low income settings in Asia and
Africa, ranging from 18% to 64%.6 7 Although the reasons for
the lower performance of live, oral vaccines in developing
countries are not fully understood, it is likely attributable to host
or environmental factors that impair a robust immune response
such as competing enteric pathogens, micronutrient malnutrition,
breast milk interference, or circulating maternal antibodies.8
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Full realization of the life saving potential of rotavirus vaccines
hinges on identifying modifiable factors associated with their
lower performance in high mortality settings.
Some 45 middle and high income countries, including 14 in
Latin America, have introduced a rotavirus vaccine in the past
seven years and consequently have experienced dramatic
reductions in the burden of severe rotavirus disease, including
indirect benefits to children who remained unvaccinated.9 Data
have been limited on the performance of rotavirus vaccines
under ordinary conditions of a public health program in high
mortality settings. A published study from Nicaragua showed
that the effectiveness of the RV5 vaccine was similar (about
50%) to that seen in the clinical trials from low income settings
in Africa and Asia.10 No data are available for the effectiveness
of the RV1 vaccine in routine programmatic use in countries
with high childhood mortality, as classified by WHO.11
Effectiveness data are particularly needed to gain a better
understanding of the benefit-risk balance because of the recent
safety concerns of a low level risk of intussusception associated
with RV1 in Mexico and Brazil.12 Thus, our primary objective
was to evaluate the effectiveness of two doses of RV1 against
hospital admissions for rotavirus in Bolivia, the first GAVI
eligible country worldwide to introduce RV1 vaccine.
Methods
Study design and setting
Bolivia is a lower-middle income country in South America
with an annual birth cohort of about 263 000 and a gross national
income of $1699 (£1092; €1284) per capita in 2009.13 The
BolivianMinistry of Health added RV1 to the routine childhood
immunization schedule in August 2008, recommending two
doses of RV1 for all children in Bolivia at 2 and 4 months of
age. From March 2010 to June 2011 we did a case-control
evaluation at six hospitals in four of the largest cities in Bolivia
(La Paz, El Alto, Cochabamba, and Santa Cruz) to assess the
effectiveness of RV1 against hospital admissions for rotavirus.
These hospitals are ministry hospitals that were selected on the
basis of WHO guidelines for rotavirus surveillance that
recommend selecting hospitals that admit more than 250 children
for gastroenteritis each year.14These six hospitals were estimated
to have 19% of all hospital admissions for diarrhea among
children before the introduction of vaccine.
Participants: cases
We defined cases as children admitted to the hospital overnight
for treatment of acute diarrhea, defined as at least three loose
stools in a 24 hour period. Inclusion criteria were onset of
diarrhea less than 14 days before the hospital visit; a rotavirus
positive stool sample during the first 48 hours of admission (to
avoid nosocomial infection); and eligibility to receive at least
one dose of RV1, defined as being born after June 1, 2008 and
being at least 8 weeks of age when admitted to hospital. We
excluded cases when we were unable to contact a parent or
care-taker to obtain consent, identify three hospital controls, or
verify vaccination status through parental card or vaccination
registry. To identify case patients, we did active hospital based
surveillance 24 hours a day in the emergency department and
inpatient wards. Bulk stool specimens were collected within 48
hours of admission. Specimens were stored at 2-8°C before
transfer to the national laboratory on a weekly basis during the
first nine months of the study and to a local laboratory during
the last six months of the study. Rotavirus testing was done with
a commercially available enzyme immunoassay (ProSpecT
ELISA, Oxoid, UK). Specimens were stored frozen at −70°C
until they were shipped to the Centers for Disease Control and
Prevention, Atlanta, GA, USA for genotyping analysis.
Genotyping was done on samples with sufficient stools, as
described by Hull et al.15
Participants: controls
We assessed effectiveness by using two groups of controls:
children admitted to hospital for conditions other than diarrhea
(that is, hospital controls) and children with rotavirus negative
diarrhea (that is, test negative controls). For non-diarrhea
hospital controls, inclusion criteria were seeking care in the
emergency department or being admitted to the same hospital
as the case for an acute illness unrelated to diarrhea or a vaccine
preventable condition (measles, mumps, rubella, diphtheria,
pertussis, tetanus, tuberculosis, hepatitis B); being born within
30 days of the case’s date of birth; and being eligible to receive
at least one dose of RV1, defined as being born after June 1,
2008 and being at least 8 weeks of age when admitted to
hospital. We excluded controls when we were unable to contact
a parent or care-taker to obtain consent, identify three hospital
controls for each case, or verify vaccination status through
parental card or vaccination registry. After a rotavirus case was
identified, we routinely queried emergency department and
hospital admission logs daily during the subsequent two weeks
to identify three consecutive hospital controls. All efforts were
made to capture the child during the hospital visit to avoid
logistical challenges of home visits and potential loss to
follow-up. We also sought to assess vaccine effectiveness by
using children with rotavirus negative diarrhea as controls (test
negative controls). Test negative controls were those children
who were enrolled during the surveillance for rotavirus diarrhea
but tested negative for rotavirus by enzyme immunoassay.
Variables
We conducted face to face interviews with parents of case
patients and hospital controls during the hospital visit. After
written informed consent had been given, we obtained
information on vaccination history, demographics,
socioeconomic factors, history of breast feeding, and medical
history. For cases, we also gathered information on clinical
characteristics, treatment, and course of illness. We selected
variables on the basis of recommendations from a WHO
guideline document on studies of the effectiveness of rotavirus
vaccines.16 The primary objective of the study was to assess
differences in antecedent exposure to the full series (two doses
versus zero) among cases compared with non-diarrhea controls
and compared with test negative controls.
Data sources
We obtained vaccination history from the parent and considered
it confirmed if the parent showed a vaccination card with the
date of vaccination, the type of vaccine used, and the name of
the child. If parents reported any vaccination but did not possess
a card, we obtained confirmation by review of vaccine cards at
the clinic where the child was reportedly vaccinated. We
identified vaccination records at the clinic on the basis of the
participant’s name, sex, and date of birth. We obtained a
photocopy of the vaccination record for cases and controls, and,
after data entry into an electronic database, we verified all RV1
vaccination dates against this record.
Sample size for vaccine effectiveness
Using a precision based approach,17we estimated that we needed
a total of 170 case patients to compute a vaccine effectiveness
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of 60% with a confidence limit width of 30%, using a matched
design with a control to case ratio of three to one and vaccine
coverage of 50%. We enrolled a total of 400 case patients to
allow for subgroup analyses including effectiveness of partial
vaccination, strain specific effectiveness, and effectiveness
stratified by age. Because we did not specifically calculate
sample sizes for the subgroup analyses (strain specific and age
stratified vaccine effectiveness), we did a post hoc power
analysis and present vaccine effectiveness results when expected
power using χ2 exceeded 80% at a significance level of 0.05
given the observed number of cases and controls for each of the
secondary outcomes.
Efforts to minimize bias
To minimize bias associated with differential surveillance and
diagnosis, we used a standard WHO recommended case
definition for severe gastroenteritis at all surveillance sites and
laboratory confirmed diagnosis of rotavirus with a validated
enzyme immunoassay with high sensitivity and specificity. For
non-diarrhea controls, we excluded children with diseases not
preventable by rotavirus vaccine because they would be less
likely to receive rotavirus vaccine than the source population
from which the cases arose. Information bias was minimized
by blinding coordinators who verified vaccination records from
knowledge of case or control status and the study hypothesis.
Efforts to determine vaccine status were similar between cases
and controls.
Statistical methods
Our primary aim was to calculate the vaccine effectiveness of
two doses of RV1 against hospital admission for rotavirus. To
assess for a potential gradient in protection by severity, we
analyzed for vaccine effectiveness against rotavirus diarrhea
with a clinical severity score of at least 11 and at least 15 on a
20 point Vesikari scoring scale that was used in the RV1 clinical
trials.4
We firstly did bivariate analyses to assess for differences in
indicators of socioeconomic condition between rotavirus case
patients and the two groups of controls to identify potential
confounders or biases for the association between RV1
vaccination and rotavirus disease. We used the Wilcoxon rank
sum test or χ2 test to assess differences.
We constructed two separate logistic regression models for
non-diarrhea and test negative controls to calculate odds ratios
with associated 95% confidence intervals.18 For both models,
we considered cases and controls to be vaccinated with the
respective number of doses (one or two) if the most recent dose
was administered 14 days before the case patient’s hospital visit
(the reference date). Children who received two doses did not
contribute to the one dose vaccine effectiveness analysis, and
children who received one dose of vaccine did not contribute
to the two dose vaccine effectiveness analysis. For non-diarrhea
controls, we used a conditional logistic regression model to
estimate the crude odds ratio, because these controls were
matched to case-patients by hospital and date of birth (±30 days).
To estimate a crude odds ratio with test negative controls
comparable to the crude odds ratio for non-diarrhea controls
generated through amatched analysis, we used an unconditional
logistic regression that included hospital, age (in months), and
month/year of birth in the base model, because test negative
controls were unmatched with regard to age and hospital during
the design phase of the study. For both control groups, we then
assessed for confounding by using multivariate modeling. To
the base models, we included all additional variables with
P<0.20 in the bivariate analyses. We then used a hierarchical
backward elimination approach to select the variables in the
final model individually, excluding those variables at a
significance level of P>0.05.19 For substantive reasons, we
retained age in months, month/year of birth, and hospital for
test negative controls. To assess for potential clustering by
hospital, we included hospital as a random effect in the
regression models, but it did not alter the model outcomes.
We did subgroup analyses to assess protection from partial dose
vaccination (that is, one dose of RV1), strain specific protection,
and protection among children 6-11 months of age compared
with those aged 12 months or over. We assessed for interaction
by age (6-11 months versus >11 months of age) and the
prevalent strains by including an interaction term for age and
vaccination and for strain type and vaccination in the model.
Finally, to assess the potential for bias in our estimates of
effectiveness, we did a “bias indicator” analysis to examine
whether two doses of RV1 provided protection against cases of
diarrhea that tested negative for rotavirus with non-diarrhea
controls, under the hypothesis that significant vaccine
effectiveness against test negative diarrhea would be due to
residual confounding in the non-diarrhea controls. For this
analysis, we compared vaccination rates among rotavirus
negative diarrhea cases and non-diarrhea controls and adjusted
for age, hospital, andmonth/year of birth by using unconditional
logistic regression.
We estimated the adjusted odds ratio by using the exponential
of the coefficient for the vaccination variable in the model. We
calculated the 95% confidence interval for the adjusted odds
ratio by using the standard error of the coefficient,18 and we
subsequently calculated vaccine effectiveness as (1−adjusted
odds ratio)×100%. Statistical significance was designated as
P<0.05. We used SAS statistical software (version 9.2) for
analyses.
Results
Participants
We approached a total of 451 case patients, 1247 non-diarrhea
controls, and 817 test negative controls. Of these, we excluded
51 (11%), 47 (4%), and 99 (12%), respectively, and the final
analysis included 400 case patients, 1200 non-diarrhea controls,
and 718 test negative controls (fig 1⇓). In comparison with
non-diarrhea controls, case patients were more likely to be male
and attend day care but less likely to have chronic underlying
illness, higher level maternal education, and telephones and
computers in their home (table 1⇓). Test-negative controls were
somewhat more similar to case-patients but also were more
likely to be male and attend day care and less likely to have
higher level maternal education and computers in their homes.
Vaccine records were confirmed for all participants in the
analysis. Adherence to the age recommendations was good;
only 10% of the children were vaccinated outside the
recommended age windows of 2 and 4 months of age (fig 2⇓).
Vaccine effectiveness estimates
We identified no difference greater than 10% between the crude
and adjusted estimates of vaccine effectiveness for either the
primary or secondary analyses in the study (tables 2⇓, 3⇓, and
4⇓). The adjusted vaccine effectiveness of a full series of two
doses of RV1 against hospital admission for rotavirus was 77%
(95% confidence interval 65% to 84%) with non-diarrhea
controls and 69% (54% to 79%) with test negative controls
(table 2⇓). One dose of RV1 also provided significant protection
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of 56% (32% to 72%) with non-diarrhea controls and 36% (0%
to 59%) with test negative controls.
Of the 400 case patients admitted to hospital for rotavirus
diarrhea, 373 (93%) had rotavirus diarrhea with a Vesikari score
of 11 or greater and 191 (48%) had a Vesikari score of 15 or
greater. Protection was similar against each of the severity
outcomes in the study. With non-diarrhea controls, RV1
provided protection of 76% (64% to 84%) for a Vesikari score
of 11 or above and 74% (54% to 85%) against a score of at least
15. When we used test negative controls, vaccine effectiveness
was 69% (53% to 79%) for Vesikari score of 11 or above and
62% (37% to 88%) for a severity score of at least 15 (table 2⇓).
Of the 400 cases, 295 had sufficient stool samples for
genotyping. Commonly detected strains included G9P[8]
(n=107; 36%), G2P[4] (74; 25%), G3P[8] (52; 18%), andG9P[6]
(23; 8%). Others were non-typeable (24; 8%) or other sparsely
detected strains (15; 5%). Vaccine effectiveness ranged from
59% to 93% against four different strains, without any
significant interaction by type of strain (P=0.70). With
non-diarrhea controls, strain specific effectiveness was 85%
(69% to 93%) and 93% (70% to 98%) against the partially
heterotypic G9P[8] and G3P[8] strains and 69% (14% to 89%)
and 87% (19% to 98%) against the fully heterotypic G2P[4]
and G9P[6] strains (table 3⇓). With test negative controls, strain
specific effectiveness was 80% (60% to 90%) and 74% (22%
to 91%) against the partially heterotypic G9P[8] and G3P[8]
strains and 59% (7% to 78%) and 80% (37% to 94%) against
the fully heterotypic G2P[4] and G9P[6] strains.
We found no significant difference in effectiveness of RV1
against hospital admission for rotavirus between the two age
groups when using non-diarrhea controls (P=0.42) or test
negative controls (P=0.35) (table 4⇓). For non-diarrhea controls,
vaccine effectiveness was 77% (51% to 89%) for children aged
6-11 months compared with76% (59% to 86%) for those aged
12 months or over. For test negative controls, vaccine
effectiveness was 64% (34% to 80%) for children aged 6-11
months compared with 72% (52% to 86%) for those aged 12
months or over. Similarly, effectiveness was high for both age
groups when we restricted the analysis to hospital admissions
with severity scores of 11 or greater and to admissions related
to the most prevalent strain, G9P[8].
In the bias indicator analysis, RV1 did not confer protection
against non-rotavirus diarrhea cases in comparison with
non-diarrhea controls for one dose (9%, −33% to 37%) or two
doses (9%, −27% to 24%) of RV1.
Discussion
Using two different sources of controls, we have shown that
RV1 vaccination under routine conditions of a public health
program in a GAVI eligible country with high child mortality
conferred protection of about 54% to 84% (lowest and highest
upper and lower confidence limits of all two dose vaccine
effectiveness estimates) against hospital admission for rotavirus.
Given the national rotavirus vaccine coverage of 80% in 2011
(increased from 65% in 2009 and 76% in 2010),20 we would
expect that vaccination is preventing some 43% to 67% of the
national burden of hospital admissions for rotavirus in Bolivia.
These are particularly encouraging findings given that the
efficacy of rotavirus vaccines has ranged from 18% to 64% in
clinical trials from other similar high mortality settings.3 6 7 We
also assessed for duration of protection and noted that
effectiveness was sustained through two years of life, the age
period within whichmost of the hospital admissions for rotavirus
occur in low and lower-middle income settings.21-23 In addition,
one dose of RV1 provided nearly 40-50% protection against
hospital admission for rotavirus in Bolivia, a finding that was
not assessed in the clinical trials. This early effect of vaccine
on rotavirus diarrhea has important implications for countries
where the burden of severe disease, particularly deaths, occurs
before the full series is administered or where children may not
return for their full series. Lastly, vaccine effectiveness was
high against the range of circulating rotavirus strains during this
evaluation, including against fully heterotypic G2P[4] and
G9P[6] strains. Taken together, these results show the powerful
effect of vaccination on improving child health in Bolivia and
offer substantial encouragement for decision makers in low and
lower-middle income countries considering introduction of
vaccine to curb the burden of severe and fatal rotavirus disease.
Comparison with other studies
In Bolivia, RV1 provided higher protection (~71-77%) against
outcomes of similar severity than RV5 provided in the low
income setting of Nicaragua (50%).10 In fact, effectiveness for
RV1 in Bolivia was similar to that for RV1 in El Salvador
(76%),24 a slightlymore developed lower-middle income country
in Central America, and comparable to RV1 efficacy for first
two years of life in the large clinical trial from 10 Latin
American countries (80%).2 In this trial, the efficacy of RV1 in
Nicaragua was 78% (18 to 96) through two years of life.25 The
differing efficacy by vaccine type might reflect a chance
occurrence, as data on effectiveness of RV5 in Latin America
are available only from a single country.10 Furthermore, in
clinical trials, the efficacy of RV1 in the first year of life in
Malawi (49%) was comparable to that of RV5 in low and
lower-middle income countries in Africa (48%) and Asia
(39%).6 7 26 The possibility of inter-study differences in case
severity might also explain some of the variation in vaccine
effectiveness; however, all studies applied comparable WHO
recommended case definitions and Vesikari severity scores,
which should have minimized this effect. As rotavirus vaccines
are introduced in additional low and lower-middle income
countries in Africa andAsia, further assessments of effectiveness
of both RV1 and RV5 in these settings to compare the
performance of the two vaccines will be important.
In clinical trials from Africa and in some post-licensure studies
from low socioeconomic settings, protection from both RV5
and RV1 seemed to be lower among children older than 1 year
compared with those aged under 1.6 24 27 28 We did not see this
phenomenon in Bolivia, which is consistent with the sustained
effectiveness of 79-83% seen through two years of life in the
large RV1 clinical trial in high and middle income countries
from Latin America.2 In addition, two studies in impoverished
populations in Brazil and Australia have suggested that RV1
(G1P[8]) effectiveness against fully heterotypic strains (such
as G2P[4]) might diminish more rapidly than that against
homotypic strains, but confidence bounds were too wide for a
meaningful conclusion.29 30 In Bolivia, we saw sustained
protection against partially heterotypic G9P[8] strains, which
is consistent with findings from the large Latin America
pre-licensure RV1 trial, but we also did not have sufficient
power to assess duration of protection against fully heterotypic
G2P[4] strains. Although these findings are encouraging, our
data should be interpreted with some caution as the study was
not specifically designed to evaluate effectiveness among
specific age groups. Such questions could be better assessed as
the vaccine program matures and additional older children are
vaccinated.
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Strengths and limitations of study
Some limitations must be considered. Estimates of vaccine
protection obtained through observational studies hinge upon
differences in exposure to vaccination between cases and
controls and thus are subject to biases relating to recording and
ascertainment of exposure. The availability of documentation
of vaccination status differed between case patients (93%), test
negative controls (88%), and non-diarrhea controls (98%) in
our study and might have biased our estimates of effectiveness
to some extent. The control population might be enriched with
non-vaccinees if controls with missing vaccine history were
more likely to be vaccinated than were cases with missing
history, which might have increased our estimates of
effectiveness. If controls with missing vaccine history had lower
vaccination rates than cases with missing history, effectiveness
estimates might be biased towards null. In addition, each of the
control groups might have its own specific biases. For example,
a false positive enzyme immunoassay result for rotavirus could
lead to misclassification of a test negative control as a case. If
the vaccine offers any protection, this would enrich the case
population with vaccinees thus falsely lowering estimates of
effectiveness. However, test negative controls have previously
proved to be good controls in studies of rotavirus vaccine
effectiveness when compared with community or non-diarrhea
controls,29 31-33 and the similarity in estimates of effectiveness
with both control groups in our study provides further
reassurance.
Although some differences in demographics and socioeconomic
indicators existed between the cases, non-diarrhea controls, and
test negative controls, we did not identify any substantial
differences between the crude and adjusted estimates of vaccine
effectiveness. However, some residual unmeasured confounding
could still be present. Bias related to health seeking behavior is
possible, but the test negative diarrhea controls are likely to
have similar healthcare seeking patterns as rotavirus diarrhea
cases and thus to be less prone to this potential bias than are
non-diarrhea controls. In addition, our bias indicator analysis
did not identify any significant bias with the non-diarrhea
controls. Lastly, if fecal shedding of RV1 leads to horizontal
transmission of vaccine virus and resultant immune response
in unvaccinated contacts of vaccine recipients, as was shown
in a clinical trial in the Dominican Republic, this might decrease
the attack rates of disease in unvaccinated children and decrease
estimates of RV1 effectiveness as measured through
observational studies.34
Conclusions and policy implications
In conclusion, our study provides evidence for protection by
RV1 vaccination against hospital admissions for rotavirus and
severe rotavirus disease caused by four different rotavirus strains
during the first two years of life in a low income setting in Latin
America. Attainment of significant protection from one dose
of RV1 also is encouraging for target populations in low and
lower-middle income settings, who can develop severe and fatal
rotavirus disease during the first few months of life. Further
research is needed to refine our understanding of the
heterogeneous immune response to rotavirus vaccines in low
socioeconomic settings. Potential strategies to improve vaccine
efficacy that warrant investigation may include altering the age
at rotavirus immunization to avoid the negative influence of
circulating maternal antibodies, decoupling rotavirus vaccines
and oral polio vaccine, and adding additional doses in the routine
schedule or as a booster with the measles dose at the end of
infancy. Although understanding the reasons for lower efficacy
is important, it should not hinder use of currently available
rotavirus vaccines. Our study provides compelling data favoring
broader use of rotavirus vaccine in low income settings to reduce
the burden of severe and fatal rotavirus disease among children.
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Tables
Table 1| Comparison of characteristics of case patients with rotavirus diarrhea, controls with non-rotavirus diarrhea, and controls with
non-diarrheal illness, March 2010 to June 2011. Values are numbers (percentages) unless stated otherwise
Controls
Cases (rotavirus
positive*) (n=400)Characteristic P valueNon-diarrhea‡ (n=1200)P value
Rotavirus negative†
(n=718)
0.27§12 (1-36)0.26§12 (2-32)12 (1-35)Median (range) age, months
<0.001642 (54)0.002400 (56)260 (65)Male sex
0.01118 (10)0.8939 (5)21 (5)Chronic underlying illness
0.0021161 (97)0.69674 (94)371 (93)History of breast feeding
0.009117 (10)<0.00157 (8)61 (15)Day care attendance
0.7113/1135 (10)0.1583/680 (12)34/367 (9)Low birth weight (<2500 g)
<0.0010.01Maternal education:
20/1194 (2)14/712 (2)7/398 (2)None
279/1194 (23)230/712 (32)119/398 (30)Primary school
591/1194 (50)311/712 (44)210/398 (53)Secondary school
304/1194 (25)157/712 (22)62/398 (16)Tertiary school
<0.001§2 (1-10)0.12§2 (1-20)2 (1-18)Median (range) No of children in
home
0.47§4 (1-20)0.86§4.0 (1-20)4.5 (1-16)Median (range) No of people in home
Socioeconomic parameters:
<0.001§4 (1-11)0.03§3 (1-11)3 (1-11)Median (range) No of rooms in home
0.921176 (98)0.56707 (98)392 (98)Electricity in home
0.14343 (29)0.97177 (25)99 (25)Own motorized vehicle
0.002353 (29)0.33171 (24)85 (21)Telephone in home
<0.001284 (24)0.04141 (20)59 (15)Computer in home
*Patients admitted to hospital or emergency department with acute gastroenteritis who had enzyme immunoassay stool testing positive for rotavirus.
†Patients admitted to hospital or emergency department with acute gastroenteritis who had enzyme immunoassay stool testing negative for rotavirus.
‡Non-diarrhea hospital controls were matched by age (±30 days) and hospital.
§P value for Wilcoxon rank sum test.
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Table 2| Effectiveness of rotavirus vaccine against rotavirus disease by severity, Bolivia
Two dose vaccinees*One dose vaccinees*
Group
Vaccine effectiveness, % (95% CI)
No/total (%)
Vaccine effectiveness, % (95% CI)
No/total (%) AdjustedCrudeAdjustedCrude
Rotavirus disease requiring hospital admission
——208/300 (69)——100/192 (52)Cases
77 (65 to 84)80 (70 to 86)857/974 (88)56 (32 to 72)57 (35 to 71)226/343 (66)Non-diarrhea
controls†
69 (54 to 79)70 (56 to 79)510/587 (87)36 (0 to 59)39 (8 to 60)131/208 (63)Test negative
controls‡
Severe rotavirus disease (Vesikari severity score ≥11)
——196/281 (70)——92/177 (52)Cases
76 (64 to 84)79 (68 to 85)803/912 (88)54 (28 to 70)55 (30 to 70)207/316 (66)Non-diarrhea
controls†
69 (53 to 79)70 (55 to 79)510/587 (87)34 (−5 to 69)42 (11 to 62)131/208 (63)Test negative
controls‡
Very severe rotavirus disease (Vesikari score ≥15)
——100/138 (72)——53/91 (58)Cases
74 (54 to 85)77 (60 to 87)407/461 (88)40 (−9 to 66)40 (−1 to 68)112/166 (67)Non-diarrhea
controls†
62 (37 to 88)66 (44 to 79)510/587 (87)6 (−63 to 78)24 (−27 to 55)131/208 (63)Test negative
controls‡
*Cases and controls were considered vaccinated with respective number of doses (one or two) if most recent dose was administered ≥14 days before date of
case’s hospital visit.
†Because non-diarrhea controls were matched on age and hospital, conditional logistic regression was used to compute odds ratio for vaccination (one or two
doses) versus no vaccination; crude vaccine effectiveness includes only vaccination in model; adjusted vaccine effectiveness for model with hospital admission
includes sex, number of children and rooms in home, and computer; model for Vesikari ≥11 includes sex and number of children and rooms in home; model for
Vesikari ≥15 includes sex and number of rooms in home.
‡Unconditional logistic regression was used to compute odds ratio for vaccination (one or two doses) versus no vaccination among cases and test negative controls;
crude vaccine effectiveness adjusts only for age in months, month/year of birth, and hospital; adjusted vaccine effectiveness for model with hospital admission
includes age in months, month/year of birth, hospital, sex, number of children and rooms in home, and computer; model for Vesikari ≥11 includes age in months,
month/year of birth, hospital, sex, and number of children and rooms in home; model for Vesikari ≥15 includes age in months, month/year of birth, hospital, sex,
and number of rooms in home.
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Table 3| Strain specific effectiveness of two doses of rotavirus vaccine* against hospital admission with rotavirus, Bolivia
Vaccine effectiveness (95% CI)
No/total (%)Group AdjustedCrude
G9P[8] hospital admission
52/77 (68)Cases
85 (69 to 93)86 (71 to 93)233/253 (92)Non-diarrhea controls†
80 (60 to 90)80 (64 to 89)510/586 (87)Test negative controls‡
G3P[8] hospital admission
30/42 (71)Cases
93 (70 to 98)92 (70 to 98)126/130 (97)Non-diarrhea controls†
74 (22 to 91)72 (23 to 89)510/586 (87)Test negative controls‡
G2P[4] hospital admission
45/56 (80)Cases
69 (14 to 89)68 (16 to 88)163/180 (91)Non-diarrhea controls†
59 (7 to 78)60 (14 to 81)510/586 (87)Test negative controls‡
G9P[6] hospital admission
7/14 (50)Cases
87 (19 to 98)88 (25 to 98)31/43 (72)Non-diarrhea controls†
80 (37 to 94)77 (33 to 93)510/586 (87)Test negative controls‡
*Cases and controls were considered vaccinated with two doses if the most recent dose was administered ≥14 days before date of case’s hospital visit.
†For non-diarrheal controls, crude vaccine effectiveness includes only vaccination in model; adjusted vaccine effectiveness for model with G9P[8] includes sex;
model for G3P[8] includes number of children rooms in home; model for G2P[4] includes number of children in home and maternal education; model for G9P[6]
includes only vaccination.
‡For test negative controls, crude vaccine effectiveness adjusts only for hospital, age in months, and month/year of birth; adjusted vaccine effectiveness for G9P[8]
includes hospital, age in months, month/year of birth, and sex; G3P[8] includes hospital, age in months, month/year of birth, sex, and maternal education; G2P[4]
includes hospital, age in months, month/year of birth, and number of children in home; G9P[6] includes hospital, age in months, and month/year of birth.
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Table 4 Effectiveness (% (95% CI)) of full series of rotavirus vaccine* against rotavirus disease stratified by age, Bolivia
Test negative controls‡Non-diarrhea controls†
Subgroups AdjustedCrudeAdjustedCrude
Rotavirus hospital admission
69 (54 to 79)70 (53 to 80)77 (65 to 84)80 (70 to 86)All ages
64 (34 to 80)65 (38 to 80)77 (51 to 89)79 (57 to 90)Age 6-11 months
72 (52 to 86)76 (62 to 87)76 (59 to 86)78 (62 to 87)Age ≥12 months
Vesikari score ≥11 (severe diarrhea)
69 (53 to 79)70 (56 to 79)76 (64 to 84)79 (68 to 85)All ages
66 (34 to 82)66 (39 to 81)78 55 to 91)79 (58 to 89)Age 6-11 months
72 (51 to 86)77 (62 to 87)76 (59 to 86)78 (63 to 87)Age ≥12 months
G9P[8] hospital admission
80 (60 to 90)80 (64 to 89)85 (69 to 93)86 (71 to 93)All ages
82 (59 to 92)81 (51 to 92)90 (65 to 97)89 (65 to 97)Age 6-11 months
78 (46 to 91)78 (73 to 95)82 (47 to 94)83 (59 to 93)Age ≥12 months
*Cases and controls were considered vaccinated with respective number of doses (one, two, or three) if most recent dose was administered ≥14 days before date
of case’s hospital visit.
†Because non-diarrhea controls were matched on age and hospital, conditional logistic regression was used to compute odds ratio for vaccination versus no
vaccination; crude vaccine effectiveness includes only vaccination in model; adjusted vaccine effectiveness for model with hospital admission includes sex, day
care, and computer for 6-11 months and sex, number of children, and rooms for ≥12 months; model for Vesikari ≥11 includes sex, day care, and telephone for
6-11 months and sex and number of children and rooms for ≥12 months; model for Vesikari ≥15 includes none for 6-11 months and sex and number of rooms for
≥12 months.
‡Unconditional logistic regression was used to compute odds ratio for vaccination versus no vaccination among cases and test negative controls; crude vaccine
effectiveness adjusts only for month/year of birth and hospital; adjusted vaccine effectiveness for model with hospital admission and Vesikari ≥11 includes month/year
of birth, hospital, sex, and day care for 6-11 months and month/year of birth, hospital, and day care for ≥12 months; adjusted model for G9P[8] includes month/year
of birth and hospital for 6-11 and ≥12 months.
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Figures
Fig 1 Flow chart depicting enrollment of rotavirus case patients, non-diarrhea controls, and test negative controls. *Children
with or without verbal history of vaccination and for whom no records were found in vaccination clinics
Fig 2 Age at rotavirus vaccine administration among rotavirus positive cases, rotavirus negative controls, and non-diarrhea
controls
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